Therapeutic combinations comprising anti-FOLR1 immunoconjugates

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10172875
APP PUB NO 20170095571A1
SERIAL NO

15268298

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • IMMUNOGEN INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Pinkas, Jan Belmont, US 7 40
Ponte, Jose Weymouth, US 10 81
Ruiz-Soto, Rodrigo R Boston, US 7 40

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 8, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 8, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00